- Home
- CINT vs NUVB Comparison
CINT vs NUVB Comparison
Compare CINT & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CINT
- NUVB
- Stock Information
- Founded
- CINT 1995
- NUVB 2018
- Country
- CINT Brazil
- NUVB United States
- Employees
- CINT N/A
- NUVB N/A
- Industry
- CINT EDP Services
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- CINT Technology
- NUVB Health Care
- Exchange
- CINT Nasdaq
- NUVB Nasdaq
- Market Cap
- CINT 833.8M
- NUVB 679.9M
- IPO Year
- CINT 2021
- NUVB N/A
- Fundamental
- Price
- CINT $5.54
- NUVB $2.13
- Analyst Decision
- CINT Buy
- NUVB Strong Buy
- Analyst Count
- CINT 7
- NUVB 5
- Target Price
- CINT $7.61
- NUVB $8.20
- AVG Volume (30 Days)
- CINT 115.3K
- NUVB 3.3M
- Earning Date
- CINT 05-21-2025
- NUVB 05-07-2025
- Dividend Yield
- CINT N/A
- NUVB N/A
- EPS Growth
- CINT 14.74
- NUVB N/A
- EPS
- CINT 0.22
- NUVB N/A
- Revenue
- CINT $438,961,000.00
- NUVB $7,873,000.00
- Revenue This Year
- CINT $533.09
- NUVB $75.73
- Revenue Next Year
- CINT $14.54
- NUVB $440.21
- P/E Ratio
- CINT $25.71
- NUVB N/A
- Revenue Growth
- CINT N/A
- NUVB N/A
- 52 Week Low
- CINT $3.34
- NUVB $1.54
- 52 Week High
- CINT $8.04
- NUVB $3.97
- Technical
- Relative Strength Index (RSI)
- CINT 50.73
- NUVB 59.35
- Support Level
- CINT $4.78
- NUVB $1.82
- Resistance Level
- CINT $5.13
- NUVB $2.23
- Average True Range (ATR)
- CINT 0.31
- NUVB 0.18
- MACD
- CINT 0.10
- NUVB 0.04
- Stochastic Oscillator
- CINT 86.43
- NUVB 84.78
About CINT CI&T Inc
CI&T Inc is engaged in providing strategy, design, and software engineering services to enable digital transformation for companies. The company mainly develops customizable software through the implementation of several software solutions, including Machine Learning, Artificial Intelligence (AI), Analytics, Cloud, and Mobility technologies. The majority of the revenue is generated from the North America and Europe, followed by Asia, Pacific and Japan.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).